# Noopept

Dipeptide-derived racetam-like nootropic; mild focus and creativity aid, cheap.

- Page: https://peprank.xyz/peptides/noopept
- Category: Focus & memory (Peptide-derived)
- Also known as: Omberacetam; GVS-111; N-phenylacetyl-L-prolylglycine ethyl ester
- Routes: Nasal / Sublingual / Oral
- Safety tier: Strict: Caution · Balanced: Caution · Evidence only: Caution
- Risk axes (0 none to 3 severe): Seen harm 1, Mechanism 1, Data gap 1, Silent harm 1, Product 2
- Positive: 39% of 50 graded reports glowing or positive, shrunk toward the 49% all-report average by 8 reports' weight
- Rank: #1 of 1 peptide-derived entries
- Graded reports: 50 (Glowing 5, Positive 14, Mixed 7, Nothing 15, Negative 6, Bad reaction 3)
- Evidence: Approved drug — approved in Russia (Noopept 10 mg tablets); small human RCTs in vascular cognitive impairment
- Access: Grey market
- Onset: Minutes to ~40 min sublingual or nasal, up to an hour oral; Russian dosing and some users describe a cumulative effect after 1-3 weeks of daily use.
- Lasts: Usually 1-4 hours per dose (some report 5-6 h); plasma half-life is under an hour.
- Cost per month: ≈ €0.34–0.68 (at 5–10 mg/day, Semax Polska at €2.25/g); oral from €0.68
- Updated: 2026-10-30

## What users report

Mixed-to-positive: 'roughly the recreational value of a cup of coffee' but easier sustained focus, sometimes reduced anxiety; strongly route-dependent (oral often does nothing, sublingual/nasal works). Perhaps 35-45% notice little. Common complaints are headaches and irritability at higher doses and insomnia for sensitive users. A small tail report anhedonia, dissociation or brain fog after a dose, usually gone in days but in one case lasting weeks.

**Effects:** easier sustained concentration; faster creative/writing work; presence, less brain fog; stimulant synergy

**Downsides:** headache (often attributed to low choline); irritability at high doses; insomnia in sensitive users; poor oral bioavailability

**Caveat:** Not really a peptide: a dipeptide-derived prodrug (to cycloprolylglycine). Over-the-counter supplement status in many countries; no serious safety signal in the Russian literature.

**Typical use:** 10-30 mg/day sublingual (or 5-10 mg nasal), split 1-2x, not daily indefinitely.

**Getting it:** Over-the-counter drug in Russia; unapproved in the US and EU, sold online as powder, capsules or nasal spray with unreliable labelling.

**Stacked with:** Choline (alpha-GPC or CDP-choline) (Most often added on the belief it prevents noopept headaches; a few users find the extra choline itself causes fatigue, reflux or low mood.); Caffeine or prescription stimulants (Adderall, modafinil) (Commonly used as an adjunct: users say it adds processing and recall to the stimulant's drive, though one reports irritability at interruptions.); L-theanine (Taken alongside to blunt the edginess or anxiety some get from noopept.)

## Risk profile

- **Seen harm 1/3:** Russian trials and an 18-study review report only mild, transient adverse events. Two first-hand reports describe lasting harm (derealization and anhedonia over seven weeks, and memory loss), which are isolated and unverified.
- **Mechanism 1/3:** A dipeptide prodrug of cycloprolylglycine that raises hippocampal NGF and BDNF in rats; no pathway to serious harm is established, and the label's only notable reaction is a rise in blood pressure in people with hypertension.
- **Data gap 1/3:** An over-the-counter drug in Russia with controlled trials (largest n=150) and a 1,279-patient systematic review of mostly open-label studies.
- **Silent harm 1/3:** Headache, overstimulation and mood effects are felt within hours, though the rare dissociative reports lingered for weeks.
- **Product 2/3:** Unapproved in the US and EU, so people buy powders, capsules and nasal sprays from nootropic vendors; US 'cognitive' supplements tested held up to four times the drug dose, 75% of declared amounts were wrong and some carried undeclared drugs.
- **Never if:** Severe liver or kidney impairment (label); Pregnancy or breastfeeding (label); Under 18 (label); Uncontrolled hypertension

## Top reports

- Glowing, focus, below the recommended dose: “I took noopept for two months, and not only I was able to sleep like a god and stay focused for hours: my daydreams were decreased by more tan 70% in terms of time, and the needing of daydream almost dissapeared.” — [r/MaladaptiveDreaming](https://www.reddit.com/r/MaladaptiveDreaming/comments/60zc88/noopept_helped_me/)
- Glowing, focus, 30 mg sublingual 3x/day in month-long courses, now about weekly: “I started in 2022 in an effort to counter brain fog and the results were pretty astonishing. ... I'm almost sixty but I feel that thanks to this stuff I have the mental capabilities I had when I was half my age.” — [r/MCAS](https://www.reddit.com/r/MCAS/comments/1tnlz9l/any_fellow_noopept_users_here/)
- Glowing, focus, 5-10 mg nasal spray: “Amino aslylums nasal spray noopept has been a god send for me, 5-10mg is all I need where oral noopept I barely felt anything” — [r/TheLongLived](https://www.reddit.com/r/TheLongLived/comments/r1vnsv/anybody_using_noopept/hm1gpqf/)
- Glowing, memory: “Noopept is best Noot for your $. I started remembering my mother who died when I was young so vividly after 2 weeks.” — [@suenraleigh on X](https://x.com/suenraleigh/status/711212160928641025)
- Glowing, neuroprotection: “I transitioned from piracetam to noopept and it broadened my thinking and made it deeper, too. ... I’ve had several head injuries and a loss of sense of smell also and I feel like has helped create plasticity” — [r/NootropicsDepot](https://www.reddit.com/r/NootropicsDepot/comments/10xg2u3/bought_noopept_pills_am_i_dumb_for_that/j7sbb81/)

## Cheapest in Europe

- [Euro Nootropics](https://euro-nootropics.com/product/noopept/) (FR): Noopept 50g, €67, €1.34/g (contents not stated on the page)
- [Euro Nootropics](https://euro-nootropics.com/product/noopept/) (FR): Noopept 20g, €37, €1.84/g (contents not stated on the page)
- [Semax Polska](https://semaxpolska.com/en/noopept-10g/) (PL): Noopept 10g, €23, €2.25/g
- [Euro Nootropics](https://euro-nootropics.com/product/noopept/) (FR): Noopept 10g, €23, €2.28/g (contents not stated on the page)
- [Euro Nootropics](https://euro-nootropics.com/product/noopept-solution/) (FR): Noopept - Solution, 600mg (20mg/mL), €30, €0.050/mg

## Studies

- [Clinical efficacy of omberacetam in adults with cognitive impairment: a systematic review](https://doi.org/10.37586/2686-8636-3-2026-335-353) (review, n=1279, 2026): 18 mostly open-label Russian studies: MMSE gains of +0.6 to +3.5 points, efficacy comparable to or above piracetam, adverse events mild and transient.
- [Dadasheva 2022: omberacetam vs piracetam/cinnarizine vs aminophenylbutyric acid in non-demented vascular cognitive impairment](https://doi.org/10.14412/2074-2711-2022-2-49-55) (rct, n=150, 2022): 10 mg twice daily for 45 days raised MoCA from 19.8 to 23.3, more than the active comparators; the gain had mostly faded 4.5 months later.
- [Neznamov & Teleshova 2009: Noopept vs piracetam in mild cognitive disorders of vascular and traumatic origin](https://pubmed.ncbi.nlm.nih.gov/19234797/) (controlled, n=53, 2009): Noopept 20 mg/day improved mild cognitive impairment about as well as piracetam 1.2 g/day, with an added anxiolytic effect and fewer side effects.
- [Amelin et al. 2011: Noopept in the treatment of mild cognitive impairment in patients with stroke](https://pubmed.ncbi.nlm.nih.gov/22500312/) (open-label, n=60, 2011): 20 mg/day for 2 months improved MMSE and verbal fluency in post-stroke patients versus controls, with good tolerability.
- [Ostrovskaya et al. 2008: Noopept stimulates the expression of NGF and BDNF in rat hippocampus](https://pubmed.ncbi.nlm.nih.gov/19240853/) (animal, 2008): Raised hippocampal NGF and BDNF mRNA after single and 28-day dosing in rats, without tolerance to the effect.

## Sources

- [Dadasheva 2022: omberacetam vs piracetam/cinnarizine in vascular cognitive impairment, n=150](https://doi.org/10.14412/2074-2711-2022-2-49-55)
- [Clinical efficacy of omberacetam in adults with cognitive impairment: systematic review (2026)](https://doi.org/10.37586/2686-8636-3-2026-335-353)